MET and cancer: Collectively, our results demonstrate that targeting the PSI domain of c-Met provides a promising therapeutic approach, and its human and mouse cross-reactivity allows successful preclinical studies to assess precise therapeutic efficacy, pharmacokinetics (PK), and toxicity profiles, resulting in the further development of IRCR201 as an ideal cancer-targeted therapeutic agent.